TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Immunotherapeutic approaches are currently the most advanced treatments for Alzheimer's disease (AD). Antibodies against amyloid β‐peptide (Aβ) bind to amyloid plaques and induce their clearance by microglia via Fc receptor‐mediated phagocytosis. Dysfunctions of microglia may play a pivotal role in AD pathogenesis and could result in reduced efficacy of antibody‐mediated Aβ clearance. Recently, heterozygous mutations in the triggering receptor expressed on myeloid cells 2 (TREM2), a microglial gene involved in phagocytosis, were genetically linked to late onset AD. Loss of TREM2 reduces the ability of microglia to engulf Aβ. We have now investigated whether loss of TREM2 affects the efficacy of immunotherapeutic approaches. We show that anti‐Aβ antibodies stimulate Aβ uptake and amyloid plaque clearance in a dose‐dependent manner in the presence or absence of TREM2. However, TREM2‐deficient N9 microglial cell lines, macrophages as well as primary microglia showed significantly reduced uptake of antibody‐bound Aβ and as a consequence reduced clearance of amyloid plaques. Titration experiments revealed that reduced efficacy of amyloid plaque clearance by Trem2 knockout cells can be compensated by elevating the concentration of therapeutic antibodies. TREM2‐deficient phagocytic cells do not uptake antibody‐bound Aβ well, resulting in reduced clearance of amyloid plaques. This, however, can be compensated by elevated concentrations of immunotherapeutic antibodies, highlighting that monitoring microglia function in Alzheimer's disease is important. TREM2‐deficient phagocytic cells do not uptake antibody‐bound Aβ well, resulting in reduced clearance of amyloid plaques. This, however, can be compensated by elevated concentrations of immunotherapeutic antibodies, highlighting that monitoring microglia function in Alzheimer's disease is important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have reported the crucial role of these genes in microglia response to Aβ and phagocytosis in AD20,21.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredIn the citing paper
“TREM2 deficiency impairs microglial phagocytosis of plaques opsonized with anti-Aβ antibodies, suggesting a critical role for TREM2 in the efficacy of antibody-based therapeutics (152).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [152]
In the citing paper
“impairment of microglia activation, as observed in TREM2-deficient mice, reduces the efficacy of the anti-Aβ antibodies (190).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [190]
In the citing paper
“With particular relevance to AD, phagocytosis of amyloid beta (Aβ) was found to be impaired due to lack of or reduced mature TREM2 cell surface expression in studies with primary microglia from Trem2 knock-out mice and mutant Trem2 microglial cell lines (30,31).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 1×
“Maximum intensity projection from each sagittal sections was then analyzed by ImageJ (Schneider et al, 2012) to obtain methoxy-X04 signal intensities.”
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 2×
“Specifically, rare heterozygous mutations in TREM2, which within the brain is exclusively expressed in microglia cells, dramatically increase the risk for late onset AD in a magnitude similar to ApoE e4 (Guerreiro et al, 2013; Jonsson et al, 2013).”
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“Specifically, rare heterozygous mutations in TREM2, which within the brain is exclusively expressed in microglia cells, dramatically increase the risk for late onset AD in a magnitude similar to ApoE e4 (Guerreiro et al, 2013; Jonsson et al, 2013).”
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 5×
“After crossing the blood–brain barrier, anti-Ab antibodies like 3D6 and others bind to amyloid plaques and trigger Fc receptor-mediated phagocytosis of plaques by microglia cells (Bard et al, 2000).”
InfluentialTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 4×
“However, attenuated Ab engulfment by microglia was thought to be due to reduced migration and survival and thus not directly associated with phagocytic activity of microglial cells (Wang et al, 2015).”
InfluentialAβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498 · cited 1×
“…approach is currently the anti-Ab immunotherapy (Wisniewski & Goni, 2015), a treatment strategy initiated after the pivotal report by Schenk et al (Schenk et al, 1999) demonstrating its efficacy in amyloid plaque removal and reduction in memory decline in an animal model (Morgan et al, 2000).”
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 1×
“Although TREM2 is well known to be involved in phagocytosis and removal of apoptotic neurons (Takahashi et al, 2005; Colonna et al, 2007; Hsieh et al, 2009), the pathological consequences of a TREM2 loss of function in the context of AD pathogenesis are highly controversial.”
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 3×
“…of whole brains from APP/PS1 mice (Radde et al, 2006) at 6 months of age, a time point where these mice are known to exhibit a high amyloid plaque burden within the brain (Radde et al, 2006). mAb11, but not the isotype control, binds selectively to the methoxy-X04-positive amyloid plaques (Fig 3B).”
Self-citationTREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840 · cited 1×
“In that regard, it is interesting to note that at very early time points of amyloid plaque deposition, Ab accumulation was similar in wt and Trem2 ko mice, but Trem2 ko mice showed reduced microglia accumulations around amyloid plaques (Wang et al, 2016).”
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 8×
“In line with our previous findings (Kleinberger et al, 2014), loss of TREM2 significantly reduced uptake of pre-aggregated HiLyteTM Fluor 488-labeled Ab42 (fAb42) (Fig 1C).”
InfluentialSelf-citationControl of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“In fact, neuregulin-1 signaling depends on biologically active b-secretase (Willem et al, 2006; Cheret et al, 2013).”
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701 · cited 1×
“Indeed, 11C-PiB positron emission tomography (PET) revealed a significant reduction in amyloid deposition in patients treated with anti-Ab antibodies (Rinne et al, 2010; Ostrowitzki et al, 2012).”
Cutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688 · cited 2×
“To investigate antibody-stimulated Ab clearance in primary phagocytic cells, we first used BMDM derived from Trem2 ko animals (Turnbull et al, 2006) or wt controls.”
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 2×
“Jay et al (2015) reported a detrimental role of TREM2 in AD by demonstrating that its knockout leads to a reduction in the amyloid plaque load, inflammation, astrogliosis, and tau phosphorylation.”
Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation
Haass, C. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600061 · Cited by 550 · cited 16×
“Obvious targets are b- and c-secretases, the two proteases, which generate the amyloid b-peptide (Ab) from its precursor, the b-amyloid precursor protein (APP) (Haass, 2004).”
InfluentialSelf-citationSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522 · cited 1×
“In that regard, we recently demonstrated that in AD patients, sTREM2 levels significantly increase very early before onset of AD and tend to decrease in later phases of the disease (Suarez-Calvet et al, 2016).”
Self-citationCrowley, M. T., Costello, P. S., Fitzer-Attas, C. J., Turner, M., Meng, F., Lowell, C., Tybulewicz, V. L. J., & DeFranco, A. L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1027 · Cited by 506 · cited 2×
“It is well known that upon stimulation of TREM2 as well as Fcc-receptors, Syk gets phosphorylated and activates a variety of downstream signaling cascades (Crowley et al, 1997; Paradowska-Gorycka & Jurkowska, 2013; Ulrich & Holtzman, 2016).”
A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475 · cited 1×
“Although TREM2 is well known to be involved in phagocytosis and removal of apoptotic neurons (Takahashi et al, 2005; Colonna et al, 2007; Hsieh et al, 2009), the pathological consequences of a TREM2 loss of function in the context of AD pathogenesis are highly controversial.”
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 15×
“For in vitro and ex vivo phagocytosis assay, the following antibodies were used: rat monoclonal antibody 2D8 against Ab1–16 (Shirotani et al, 2007), rabbit polyclonal antibody 6687 against cytosolic domain of APP (Capell et al, 2000), mouse IgG2a isotype control (Sigma-Aldrich), and mouse monoclonal mAb11 (IgG2a (Bohr…”
InfluentialSelf-citationMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“Indeed, 11C-PiB positron emission tomography (PET) revealed a significant reduction in amyloid deposition in patients treated with anti-Ab antibodies (Rinne et al, 2010; Ostrowitzki et al, 2012).”
TREM2 variants: new keys to decipher Alzheimer disease pathogenesis
Colonna, M., & Wang, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.7 · Cited by 418 · cited 1×
“…AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease (Guerreiro et al, 2013; Jonsson et al, 2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers et al, 2014; Colonna & Wang, 2016; Ulrich & Holtzman, 2016; Villegas-Llerena et al, 2016).”
Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease
McGeer, P. L., & Rogers, J. (1992) · Neurology · doi:10.1212/wnl.42.2.447 · Cited by 406 · cited 1×
“A pivotal role of microglia and inflammatory mechanisms in AD and other neurodegenerative disorders, which was already emphasized early during AD research (McGeer & Rogers, 1992), was recently strongly supported by genetic evidence (Villegas-Llerena et al, 2016).”
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404 · cited 1×
“…risk for AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease (Guerreiro et al, 2013; Jonsson et al, 2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers et al, 2014; Colonna & Wang, 2016; Ulrich & Holtzman, 2016; Villegas-Llerena…”
η-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398 · cited 1×
“Similarly, recent findings may also indicate that inhibition of b-secretase may be problematic due to the accumulation of alternative neurotoxic APP-derived fragments (Willem et al, 2015).”
Self-citationMarim, F. M., Silveira, T. N., Lima, D. S., & Zamboni, D. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015263 · Cited by 351 · cited 1×
“Bone marrow-derived macrophages culture Bone marrow-derived macrophages (BMDM) were prepared essentially as described before (Marim et al, 2010).”
Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons
Kuhn, P., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.173 · Cited by 301 · cited 1×
“Moreover, b-secretase has numerous brain-specific substrates and their biological function may be disturbed upon inhibition of shedding (Kuhn et al, 2012; Zhou et al, 2012; Barao et al, 2016).”
Self-citationTREM2 regulates microglial cell activation in response to demyelination in vivo
Cantoni, C., Bollman, B., Licastro, D., Xie, M., Mikesell, R., Schmidt, R., Yuede, C. M., Galimberti, D., Olivecrona, G., Klein, R. S., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1388-1 · Cited by 296 · cited 1×
“Similarly, in a cuprizone model for acute demyelination, TREM2-deficient mice showed reduced phagocytic removal of myelin debris (Cantoni et al, 2015).”
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 2×
“Anti-Ab immunotherapy is currently a promising and clinically advanced approach (Wisniewski & Goni, 2015).”
Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease
Villegas-Llerena, C., Phillips, A., Garcia-Reitboeck, P., Hardy, J., & Pocock, J. M. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.10.004 · Cited by 270 · cited 2×
“A pivotal role of microglia and inflammatory mechanisms in AD and other neurodegenerative disorders, which was already emphasized early during AD research (McGeer & Rogers, 1992), was recently strongly supported by genetic evidence (Villegas-Llerena et al, 2016).”
TREM2 Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis
Cady, J., Koval, E. D., Benitez, B. A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., Baloh, R. H., Ravits, J., Simpson, E., Appel, S. H., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6237 · Cited by 262 · cited 1×
“…AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease (Guerreiro et al, 2013; Jonsson et al, 2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers et al, 2014; Colonna & Wang, 2016; Ulrich & Holtzman, 2016; Villegas-Llerena et al, 2016).”
Greenberg, S., Chang, P., & Silverstein, S. C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41945-4 · Cited by 237 · cited 1×
“Indeed, it has been shown previously that Syk phosphorylation is an important signaling event upon Fcc-receptors activation in macrophage phagocytosis (Greenberg et al, 1994; Crowley et al, 1997).”
TREM-2 promotes macrophage survival and lung disease after respiratory viral infection
Wu, K., Byers, D. E., Jin, X., Agapov, E., Alexander-Brett, J., Patel, A. C., Cella, M., Gilfilan, S., Colonna, M., Kober, D. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141732 · Cited by 207 · cited 1×
“Moreover, since TREM2 affects survival of microglial cells (Wang et al, 2015; Wu et al, 2015), the age as well as the specific mouse model used for the investigation must be carefully considered.”
Cuyvers, E., Bettens, K., Philtjens, S., Van Langenhove, T., Gijselinck, I., van der Zee, J., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Geerts, N., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.009 · Cited by 182 · cited 1×
“…AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease (Guerreiro et al, 2013; Jonsson et al, 2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers et al, 2014; Colonna & Wang, 2016; Ulrich & Holtzman, 2016; Villegas-Llerena et al, 2016).”
Heterozygous TREM2 mutations in frontotemporal dementia
Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., Fenoglio, C., Piaceri, I., Archetti, S., Bonvicini, C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.017 · Cited by 173 · cited 1×
“…AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease (Guerreiro et al, 2013; Jonsson et al, 2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers et al, 2014; Colonna & Wang, 2016; Ulrich & Holtzman, 2016; Villegas-Llerena et al, 2016).”
The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo
Zhou, L., Barão, S., Laga, M., Bockstael, K., Borgers, M., Gijsen, H., Annaert, W., Moechars, D., Mercken, M., Gevaer, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377465 · Cited by 167 · cited 1×
“Moreover, b-secretase has numerous brain-specific substrates and their biological function may be disturbed upon inhibition of shedding (Kuhn et al, 2012; Zhou et al, 2012; Barao et al, 2016).”
Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch
Capell, A., Steiner, H., Romig, H., Keck, S., Baader, M., Grim, M. G., Baumeister, R., & Haass, C. (2000) · Nature Cell Biology · doi:10.1038/35008626 · Cited by 166 · cited 2×
“As a negative control, we used antibody 6687 raised to the C-terminus of APP (Capell et al, 2000).”
Self-citationSessa, G., Podini, P., Mariani, M., Meroni, A., Spreafico, R., Sinigaglia, F., Colonna, M., Panina, P., & Meldolesi, J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03729.x · Cited by 165 · cited 2×
“TREM2 deficiency reduces uptake efficacy of antibody-bound Ab by phagocytic cells To investigate a potential influence of TREM2 deficiency on antibody-mediated Ab clearance, we first studied Ab uptake in the microglial cell line N9 (Sessa et al, 2004).”
BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
Barão, S., Moechars, D., Lichtenthaler, S. F., & De Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 158 · cited 1×
“Moreover, b-secretase has numerous brain-specific substrates and their biological function may be disturbed upon inhibition of shedding (Kuhn et al, 2012; Zhou et al, 2012; Barao et al, 2016).”
TREM2 Function in Alzheimer’s Disease and Neurodegeneration
Ulrich, J. D., & Holtzman, D. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00313 · Cited by 154 · cited 2×
“…AD, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease (Guerreiro et al, 2013; Jonsson et al, 2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers et al, 2014; Colonna & Wang, 2016; Ulrich & Holtzman, 2016; Villegas-Llerena et al, 2016).”
Bace1 and Neuregulin‐1 cooperate to control formation and maintenance of muscle spindles
Cheret, C., Willem, M., Fricker, F. R., Wende, H., Wulf‐Goldenberg, A., Tahirovic, S., Nave, K., Saftig, P., Haass, C., Garratt, A. N., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.146 · Cited by 124 · cited 1×
“In fact, neuregulin-1 signaling depends on biologically active b-secretase (Willem et al, 2006; Cheret et al, 2013).”
Self-citationStructure, expression pattern and biological activity of molecular complex TREM-2/DAP12
Paradowska-Gorycka, A., & Jurkowska, M. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.02.003 · Cited by 103 · cited 1×
“It is well known that upon stimulation of TREM2 as well as Fcc-receptors, Syk gets phosphorylated and activates a variety of downstream signaling cascades (Crowley et al, 1997; Paradowska-Gorycka & Jurkowska, 2013; Ulrich & Holtzman, 2016).”
Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptidesi
Fleisher-Berkovich, S., Filipovich-Rimon, T., Ben-Shmuel, S., Hülsmann, C., Kummer, M. P., & Heneka, M. T. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-61 · Cited by 80 · cited 1×
“Primary murine microglial cultures were prepared as previously described (Fleisher-Berkovich et al, 2010).”
Shirotani, K., Tomioka, M., Kremmer, E., Haass, C., & Steiner, H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.011 · Cited by 68 · cited 5×
“For in vitro and ex vivo phagocytosis assay, the following antibodies were used: rat monoclonal antibody 2D8 against Ab1–16 (Shirotani et al, 2007), rabbit polyclonal antibody 6687 against cytosolic domain of APP (Capell et al, 2000), mouse IgG2a isotype control (Sigma-Aldrich), and mouse…”
InfluentialSelf-citationThe Enigmatic Function of TREM-2 in Osteoclastogenesis
Colonna, M., Turnbull, I. R., & Klesney‐Tait, J. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_13 · Cited by 56 · cited 1×
“Although TREM2 is well known to be involved in phagocytosis and removal of apoptotic neurons (Takahashi et al, 2005; Colonna et al, 2007; Hsieh et al, 2009), the pathological consequences of a TREM2 loss of function in the context of AD pathogenesis are highly controversial.”
Antibody drugs for Alzheimer’s show glimmers of promise
Reardon, S. (2015) · Nature · doi:10.1038/nature.2015.18031 · Cited by 55 · cited 2×
“Although initially there was no obvious beneficial effect on memory, data from two recent clinical trials now suggest that immunotherapy may significantly slow memory decline (Reardon, 2015).”
TREM2 and Risk of Alzheimer’s Disease — Friend or Foe?
Tanzi, R. E. (2015) · New England Journal of Medicine · doi:10.1056/nejmcibr1503954 · Cited by 52 · cited 1×
“This discrepancy may be due to the use of different mouse models, but also due to the fact that microglial function may be differentially compromised depending on the time point one investigates amyloid pathology (Tanzi, 2015).”
Lathuilière, A., Laversenne, V., Astolfo, A., Kopetzki, E., Jacobsen, H., Stampanoni, M., Bohrmann, B., Schneider, B. L., & Aebischer, P. (2016) · Brain · doi:10.1093/brain/aww036 · Cited by 46 · cited 15×
“For in vitro and ex vivo phagocytosis assay, the following antibodies were used: rat monoclonal antibody 2D8 against Ab1–16 (Shirotani et al, 2007), rabbit polyclonal antibody 6687 against cytosolic domain of APP (Capell et al, 2000), mouse IgG2a isotype control (Sigma-Aldrich), and mouse monoclonal mAb11 (IgG2a (Bohr…”
InfluentialSelf-citation
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner
Jaitin, D. A., Adlung, L., Thaiss, C. A., Weiner, A., Li, B., Descamps, H., Lundgren, P., Bleriot, C., Liu, Z., Deczkowska, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.054 · Cited by 1,377
“Christian Haass, Ludwig-Maximilians University Munich, Germany;(Xiang et al., 2016)) together with CD9, perilipin-1 and DAPI.”
InfluentialAlzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
Metadata
- Authors
- Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- F. Hoffmann-La Roche AG (CH)
- Munich Cluster for Systems Neurology (DE)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Haass, Christian
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2016-07-08
- Volume
- 8
- Issue
- 9
- Pages
- 992-1004
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC5009806
- OpenAlex
- W2473453806
- Cited by
- 183
- References
- 53
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 11 · 2023: 15 · 2022: 15 · 2021: 18 · 2020: 30 · 2019: 20 · 2018: 21 · 2017: 23 · 2016: 4
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- Site cant be reached (submittedVersion)
- DZNE Pub (submittedVersion, other-oa)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Journal of Neurochemistry
- Funders
- Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy)
- European Research Council (ERC grant Agreement No. 321366‐Amyloid)
- Legacy of Mrs. Ammer
- The MetLife Award
- Cure Alzheimer's Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- TREM2, Alzheimer's disease, amyloid-beta, anti-amyloid immunotherapy, microglia, phagocytosis, amyloid plaque clearance, macrophages, Fc receptors
- MeSH terms
- Amyloid, Animals, Cells, Cultured, Membrane Glycoproteins, Mice, Inbred C57BL, Neuroglia, Phagocytosis, Receptors, Immunologic, Mice, Knockout
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.